The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension
Open accessAbstract
BACKGROUND: Recently, a cluster of patients was observed in France in whom primary pulmonary hypertension developed in patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. METHODS: In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. RESULTS: The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used to a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. CONCLUSIONS: The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since their use is expected to increase in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Pulmonary Hypertension
Rich, S., DANTZKER, D. R., AYRES, S. M., BERGOFSKY, E. H., BRUNDAGE, B. H., Detre, K. M., FISHMAN, A. P., GOLDRING, R. M., GROVES, B. M., KOERNER, S. K., et al. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-216 · Cited by 2,027
Self-citationThe Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,558
Self-citationTreatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)
Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J., & Long, W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-7-485 · Cited by 701
Increased plasma serotonin in primary pulmonary hypertension
Hervé, P., Launay, J., Scrobohaci, M.-L., Brenot, F., Simonneau, G., PETITPRETZ, P., Poubeau, P., Cerrina, J., Duroux, P., & Drouet, L. O. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80156-9 · Cited by 557
Self-citationHadengue, A., Benhayoun, M. K., Lebrec, D., & Benhamou, J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90225-a · Cited by 497
Primary Pulmonary Hypertension and Cirrhosis: Are They Related?
McDonnell, P. J., Toye, P. A., & Hutchins, G. M. (1983) · American Review of Respiratory Disease · doi:10.1164/arrd.1983.127.4.437 · Cited by 318
Primary Pulmonary Hypertension
Rubin, L. J. (1993) · CHEST Journal · doi:10.1378/chest.104.1.236 · Cited by 308
Primary pulmonary hypertension and fenfluramine use.
Brénot, F., Hervé, P., PETITPRETZ, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 247
Self-citationPETITPRETZ, P., Brénot, F., Azarian, R., Parent, F., Rain, B., Hervé, P., & Simonneau, G. (1994) · Circulation · doi:10.1161/01.cir.89.6.2722 · Cited by 238
Self-citationPulmonary hypertension and fenfluramine
Douglas, J. G., Munro, J., KITCHIN, A. H., Muir, A. L., & Proudfoot, A. T. (1981) · BMJ · doi:10.1136/bmj.283.6296.881 · Cited by 180
Research works printed but not linked: 3
- Gurtner HP, 1985, Cor Vasa, 27, 160
- Michelakis ED, 1995, Am J Respir Crit Care Med, 151, A725
- Russel LA, 1992, Am Rev Respir Dis, 145, A717
Cited by
Sorted by citations
Items 201–300 of 999
Kelley, E. E., Baust, J., Bonacci, G., Golin-Bisello, F., Devlin, J. E., St. Croix, C. M., Watkins, S. C., Gor, S., Cantu-Medellin, N., Weidert, E. R., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvt341 · Cited by 95
Treating the Obese Patient: Suggestions for Primary Care Practice
Anderson, D. A. (1999) · Archives of Family Medicine · doi:10.1001/archfami.8.2.156 · Cited by 95
5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure
Janssen, W., Schymura, Y., Novoyatleva, T., Kojonazarov, B. K., Boehm, M., Wietelmann, A., Luitel, H., Murmann, K., Krompiec, D., Tretyn, A., et al. (2015) · BioMed Research International · doi:10.1155/2015/438403 · Cited by 94
Davis, R., & Faulds, D. M. (1996) · Drugs · doi:10.2165/00003495-199652050-00007 · Cited by 93
Pharmacotherapy for Obesity — Do the Benefits Outweigh the Risks?
Manson, J. E., & Faich, G. A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350910 · Cited by 93
Pulmonary hypertension associated with benfluorex exposure
Savale, L., Chaumais, M., Cottin, V., Bergot, E., Frachon, I., Prévôt, G., Pison, C. M., Dromer, C., Poubeau, P., Lamblin, N., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00188611 · Cited by 92
Self-citationObesity and reproduction: an educational bulletin
(2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.08.005 · Cited by 91
Wadden, T. A., Berkowitz, R. I., Vogt, R. A., Steen, S. N., Stunkard, A. J., & Foster, G. D. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00296.x · Cited by 92
Rare diseases bullet 5: Primary pulmonary hypertension
Peacock, A. (1999) · Thorax · doi:10.1136/thx.54.12.1107 · Cited by 92
Role of Pharmacovigilance in India: An overview
Suke, S. G., Kosta, P., & Negi, H. (2015) · Online Journal of Public Health Informatics · doi:10.5210/ojphi.v7i2.5595 · Cited by 101
Benfluorex and Unexplained Valvular Heart Disease: A Case-Control Study
Frachon, I., ETIENNE, Y., Jobic, Y., Gal, G. L., Humbert, M. J. C., & Leroyer, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010128 · Cited by 89
Kafi, S. A., Mélot, C., Vachiéry, J., Brimioulle, S., & Naeije, R. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00091-6 · Cited by 89
Epidemiology of Pulmonary Arterial Hypertension
Taichman, D. B., & Mandel, J. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.08.010 · Cited by 88
Veyssier-Belot, C. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00230-8 · Cited by 87
Temporal trends and drug exposures in pulmonary hypertension: An American experience
Walker, A. M., Langleben, D., Korelitz, J., Rich, S., Rubin, L. J., Strom, B. L., Gonin, R., Keast, S., Badesch, D. B., Barst, R. J., et al. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.02.020 · Cited by 86
Self-citationTherapeutic targets in pulmonary arterial hypertension
Rhodes, C. J., Davidson, A., Gibbs, J. S. R., Wharton, J., & Wilkins, M. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.002 · Cited by 88
Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome
Schoonjans, A., Lagae, L. G., & Ceulemans, B. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615607726 · Cited by 82
Potassium channels in pulmonary arterial hypertension
Boucherat, O., Chabot, S., Antigny, F., Perros, F., Provencher, S., & Bonnet, S. (2015) · European Respiratory Journal · doi:10.1183/13993003.00798-2015 · Cited by 84
Impaired Release of ATP from Red Blood Cells of Humans with Primary Pulmonary Hypertension
Sprague, R. S., Stephenson, A. H., Ellsworth, M. L., Keller, C. A., & Lonigro, A. J. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122600507 · Cited by 84
Bosentan: a dual endothelin receptor antagonist
Roux, S., & Rubin, L. J. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.7.991 · Cited by 84
Boswell, R. G., Potenza, M. N., & Grilo, C. M. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.10.014 · Cited by 89
Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs
Azuaje, F. J., Zhang, L., Devaux, Y., & Wagner, D. R. (2011) · Scientific Reports · doi:10.1038/srep00052 · Cited by 81
Pharmacotherapy for childhood obesity: present and future prospects
Sherafat‐Kazemzadeh, R., Yanovski, S. Z., & Yanovski, J. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.144 · Cited by 83
Pulmonary arterial hypertension
Raiesdana, A., & Loscalzo, J. (2006) · Annals of Medicine · doi:10.1080/07853890600622143 · Cited by 81
Eddahibi, S., & Adnot, S. (2001) · Respiratory Research · doi:10.1186/rr181 · Cited by 77
Grimaldi‐Bensouda, L., Alpérovitch, A., Besson, G., Vial, C., Cuisset, J., Papeix, C., Lyon‐Caen, O., Bénichou, J., Rossignol, M., & Lucien Abenhaim for the GBS-PGRx Study Group (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr072 · Cited by 76
Pulmonary arterial hypertension specific therapy: The old and the new
Zolty, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107576 · Cited by 75
Wideman, R. F., Chapman, M. E., Hamal, K. R., Bowen, O. T., Lorenzoni, A. G., Erf, G. F., & Anthony, N. B. (2007) · Poultry Science · doi:10.1093/ps/86.5.984 · Cited by 76
Fortnightly Review: Insulin resistance
Krentz, A. J. (1996) · BMJ · doi:10.1136/bmj.313.7069.1385 · Cited by 76
Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies
Tomic, D., Kemp, W. W., & Roberts, S. K. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001235 · Cited by 76
5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists as Potential Antiobesity Agents
Nilsson, B. M. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm058240i · Cited by 75
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 77
Dempsie, Y., MacRitchie, N. A., White, K., Morecroft, I., Wright, A. F., Nilsen, M., Loughlin, L., Mair, K. M., & MacLean, M. R. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt064 · Cited by 74
Serotonin and Appetite Regulation
Blundell, J. E., & Halford, J. C. G. (1998) · CNS Drugs · doi:10.2165/00023210-199809060-00005 · Cited by 74
Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals
Dahl, C. F., Allen, M. R., Urie, P. M., & Hopkins, P. N. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-34 · Cited by 73
Pharmacological treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200024 · Cited by 73
Fenfluramine-like cardiovascular side-effects of benfluorex
Boutet, K., Frachon, I., Jobic, Y., Gut‐Gobert, C., Leroyer, C., Carlhant-Kowalski, D., Sitbon, O., Simonneau, G., & Humbert, M. J. C. (2009) · European Respiratory Journal · doi:10.1183/09031936.00086308 · Cited by 73
Self-citationDrug-associated pulmonary arterial hypertension
McGee, M., Whitehead, N., Martin, J. H., & Collins, N. J. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1447119 · Cited by 73
Serotonin Modulation of Macrophage Polarization: Inflammation and Beyond
Casas-Engel, M. D. L., & Corbí, A. L. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-07320-0_9 · Cited by 76
Pulmonary Arterial Hypertension
Dodson, M. W., Brown, L. M., & Elliott, C. G. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.02.003 · Cited by 72
Monoclonal Endothelial Cells in Appetite Suppressant–associated Pulmonary Hypertension
Tuder, R. M., Radisavljevic, Z., Shroyer, K. R., Polak, J. M., & Voelkel, N. F. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.6.9805002 · Cited by 72
Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension?
Eddahibi, S., Raffestin, B., Hamon, M., & Adnot, S. (2002) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2002.122181 · Cited by 72
Waxman, A. B., & Zamanian, R. T. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.002 · Cited by 71
Izikki, M., Hanoun, N., Marcos, É., Savale, L., Barlier‐Mur, A., Saurini, F., Eddahibi, S., Hamon, M., & Adnot, S. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00082.2007 · Cited by 71
Pulmonary Hypertension and Right Ventricular Dysfunction: Physiology and Perioperative Management
Strumpher, J., & Jacobsohn, E. (2011) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2011.02.022 · Cited by 72
Activation of GATA-4 by Serotonin in Pulmonary Artery Smooth Muscle Cells
Suzuki, Y., Day, R. M., Tan, C. C., Sandven, T. H., Liang, Q., Molkentin, J. D., & Fanburg, B. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210465200 · Cited by 71
Treatment of non-alcoholic steatohepatitis
Angulo, P., & Lindor, K. D. (2002) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2002.0327 · Cited by 71
Finer, N. (2002) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1053/beem.2002.0231 · Cited by 71
Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
Heal, D. J., Gosden, J., & Smith, S. L. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03549.x · Cited by 86
Ireland, N. P. H. C. O. T. U. A. (2008) · Heart · doi:10.1136/hrt.2007.132118 · Cited by 115
Pathogenesis of HIV‐Related Pulmonary Hypertension
Pellicelli, A. M., Palmieri, F., Cicalini, S., & Petrosillo, N. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03904.x · Cited by 70
Sullivan, J. E., Scheffer, I. E., Lagae, L. G., Nabbout, R., Pringsheim, M., Talwar, D., Polster, T., Galer, B. S., Lock, M. D., Agarwal, A., et al. (2020) · Epilepsia · doi:10.1111/epi.16722 · Cited by 69
Current Concepts in the Pharmacological Management of Obesity
Carek, P. J., & Dickerson, L. M. (1999) · Drugs · doi:10.2165/00003495-199957060-00005 · Cited by 69
Ion channels in pulmonary arterial hypertension
Mandegar, M., Remillard, C. V., & Yuan, J. X. ‐. (2002) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2002.127491 · Cited by 68
New and Emerging Drug Molecules Against Obesity
George, M., Rajaram, M., & Shanmugam, E. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501017 · Cited by 68
Serotonin as a Mitogen in the Gastrointestinal Tract: Revisiting a Familiar Molecule in a New Role
Shah, P. A., Park, C. J., Shaughnessy, M. P., & Cowles, R. A. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.05.008 · Cited by 70
Drug-induced valvular heart disease: An update
Andréjak, M., & Tribouilloy, C. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.02.003 · Cited by 67
Dual dopamine/serotonin releasers: Potential treatment agents for stimulant addiction.
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0014103 · Cited by 69
Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?
MacLean, M. R. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01389-9 · Cited by 67
Editorials and Conflicts of Interest
Angell, M. E., & Kassirer, J. P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351410 · Cited by 67
Key role of the RhoA/Rho kinase system in pulmonary hypertension
Connolly, M., & Aaronson, P. I. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.09.001 · Cited by 66
5-HT2C Receptor Agonists and the Control of Appetite
Halford, J. C. G., & Harrold, J. A. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-24716-3_16 · Cited by 69
A case-control study to assess the risk of immune thrombocytopenia associated with vaccines
Grimaldi‐Bensouda, L., Michel, M., Aubrun, E., Leighton, P., Viallard, J., Adoué, D., Magy-Bertrand, N., Tisserand, G., Khellaf, M., Durand, J. M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431098 · Cited by 66
Self-citationPrimary Pulmonary Hypertension In Israel
Appelbaum, L., Yigla, M., Bendayan, D., Reichart, N., Fink, G., Priel, I. E., Schwartz, Y., Richman, P. S., Picard, E., Goldman, S., et al. (2001) · CHEST Journal · doi:10.1378/chest.119.6.1801 · Cited by 66
Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Elangbam, C. S. (2008) · Veterinary Pathology · doi:10.1354/vp.46-1-10 · Cited by 66
The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension
Michelakis, E. D. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7960-5_19 · Cited by 66
Drug-Induced Respiratory Disorders
Ben-Noun, L. L. (2000) · Drug Safety · doi:10.2165/00002018-200023020-00005 · Cited by 65
Genetics of pulmonary hypertension: from bench to bedside
Humbert, M. J. C., & Trembath, R. C. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.02702002 · Cited by 64
Endothelin-1 and serotonin: Mediators of primary and secondary pulmonary hypertension?
MacLean, M. R. (1999) · Journal of Laboratory and Clinical Medicine · doi:10.1016/s0022-2143(99)90114-2 · Cited by 64
Pulmonary arterial hypertension: New insights and new hope
Martin, K. B., Klinger, J. R., & Rounds, S. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00778.x · Cited by 64
Mélot, C., & Naeije, R. (2011) · Comprehensive physiology · doi:10.1002/cphy.c090014 · Cited by 64
Bae, Y. M., Kim, A., Kim, J.-H., Park, S. W., Kim, T., Lee, Y. R., Kim, B., & Cho, S. I. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.116 · Cited by 63
Serotonergic Anti-Obesity Agents
Halford, J. C. G., Boyland, E. J., Lawton, C. L., Blundell, J. E., & Harrold, J. A. (2011) · Drugs · doi:10.2165/11596680-000000000-00000 · Cited by 62
Effects on serotonin in rat hypothalamus of d-fenfluramine, aminorex, phentermine and fluoxetine
Tao, R., Fray, A. E., Aspley, S., Brammer, R. J., Heal, D. J., & Auerbach, S. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01751-x · Cited by 63
Greenway, F. L., & Caruso, M. K. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.6.1083 · Cited by 62
Major histocompatibility (B) complex control of responses against Rous sarcomas
Taylor, R. (2004) · Poultry Science · doi:10.1093/ps/83.4.638 · Cited by 62
Cellular pathophysiology and therapy of pulmonary hypertension
Olschewski, H., Rose, F., Grünig, E., Ghofrani, H. A., WALMRATH, D., Schulz, R., SCHERMULY, R. T., Grimminger, F., & Seeger, W. (2001) · Journal of Laboratory and Clinical Medicine · doi:10.1067/mlc.2001.119285 · Cited by 62
Characterization of phentermine and related compounds as monoamine oxidase (mao) inhibitors
Ulus, İ. H., Maher, T. J., & Wurtman, R. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00306-3 · Cited by 62
Ahmadi, N., Eshaghian, S., Huizenga, R., Sosnin, K., Ebrahimi, R., & Siegel, R. J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.02.032 · Cited by 61
Doggrell, S. A. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.5.805 · Cited by 61
Valvular Heart Disease Associated with Dexfenfluramine
Cannistra, L. B., Davis, S. M., & Bauman, A. G. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370912 · Cited by 61
Thrombotic Thrombocytopenic Purpura and Clopidogrel — A Need for New Approaches to Drug Safety
Wood, A. J. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422410 · Cited by 61
Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know
Odi, R., Invernizzi, R. W., Gallily, T., Bialer, M., & Perucca, E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107866 · Cited by 60
Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis
Humbert, M. J. C., Labrune, P., Sitbon, O., Gall, C., Callebert, J., Hervé, P., Samuel, D., Machado, R. D., Trembath, R. C., Drouet, L. O., et al. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00258702 · Cited by 60
Self-citationFantozzi, I., Platoshyn, O., Wong, A. H., Zhang, S., Remillard, C. V., Furtado, M. R., Petrauskene, O., & Yuan, J. X. ‐. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00191.2005 · Cited by 60
Sun, C., Lee, F.-Y., Sheu, J., Yuen, C.-M., Chua, S. O., Chung, S., Chai, H., Chen, Y.-T., Kao, Y. H., Chang, L., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154328 · Cited by 60
The Pharmacologic Approach to the Treatment of Obesity
Weiser, M. C., Frishman, W. H., Michaelson, M. D., & Abdeen, M. A. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04323.x · Cited by 60
United States Pulmonary Hypertension Scientific Registry
Badlam, J. B., Badesch, D. B., Austin, E. D., Benza, R. L., Chung, W. K., Farber, H. W., Feldkircher, K., Frost, A., Poms, A. D., Lutz, K. A., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.088 · Cited by 60
Regulation of bone morphogenetic protein signalling in human pulmonary vascular development
Southwood, M. R., Jeffery, T. K., Xu, Y., Upton, P., Hall, S., Atkinson, C., Haworth, S. G., Stewart, S., Reynolds, P. N., Long, L., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2261 · Cited by 59
Looking to the future: a new decade of pulmonary arterial hypertension therapy
McLaughlin, V. V. (2011) · European Respiratory Review · doi:10.1183/09059180.00006411 · Cited by 59
Orcholski, M. E., Khurshudyan, A., Shamskhou, E. A., Yuan, K., Chen, I. Y., Kodani, S. D., Morisseau, C. H. P., Hammock, B. D., Hong, E. M., Alexandrova, L. А., et al. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00453.2016 · Cited by 59
Classification and pathophysiology of pulmonary hypertension
Sysol, J. R., & Machado, R. F. (2018) · Continuing Cardiology Education · doi:10.1002/cce2.71 · Cited by 65
A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
Nisoli, E., & Carruba, M. O. (2003) · Drug Safety · doi:10.2165/00002018-200326140-00004 · Cited by 58
Mortality From Primary Pulmonary Hypertension in the United States, 1979–1996
Lilienfeld, D. E., & Rubin, L. J. (2000) · CHEST Journal · doi:10.1378/chest.117.3.796 · Cited by 59
Effects of Anorexinogen Agents on Cloned Voltage-Gated K+ Channel hKv1.5
Perchenet, L., Hilfiger, L., Mizrahi, J. L., & Clément‐Chomienne, O. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29480-5 · Cited by 59
Pharmacological treatment of obesity: present status
Scheen, A. J., & Lefèbvre, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800795 · Cited by 59
Rossi, S. S., Odoardi, S., Castrignanò, E., Serpelloni, G., & Chiarotti, M. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.06.011 · Cited by 58
El‐Bizri, N., Guignabert, C., Wang, L., Cheng, A., Stankunas, K., Chang, C., Mishina, Y. M., & Rabinovitch, M. (2008) · Development · doi:10.1242/dev.017863 · Cited by 58
The potential use of selective 5-HT2Cagonists in treating obesity
Smith, B. M., Thomsen, W. J., & Grottick, A. J. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.3.257 · Cited by 57
Metadata
- Authors
- Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., Simonneau, G., & Bégaud, B.
- Affiliations
- Jewish General Hospital (CA)
- Hôpital Antoine-Béclère (FR)
- University of Illinois Chicago (US)
- Centre Hospitalier Universitaire de Liège (BE)
- University of Sheffield (GB)
- Hammersmith Hospital (GB)
- Maastricht University Medical Centre (NL)
- Hôpital Bichat-Claude-Bernard (FR)
- Hôpital Pellegrin (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-08-29
- Volume
- 335
- Issue
- 9
- Pages
- 609-616
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2329065056
- Cited by
- 1,162
- References
- 26
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 22 · 2023: 21 · 2022: 22 · 2021: 16 · 2020: 16 · 2019: 20 · 2018: 27 · 2017: 29 · 2016: 18 · 2015: 30 · 2014: 27 · 2013: 39 · 2012: 34
- FWCI
- 71.92
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- idiopathic pulmonary arterial hypertension, appetite suppressants, drug-induced pulmonary hypertension, risk factors, HIV infection, liver cirrhosis, cocaine use, intravenous drug use, weight management
- MeSH terms
- Adolescent, Adult, Aged, Appetite Depressants, Belgium, Female, Fenfluramine, France, United Kingdom, Heart Function Tests, Hemodynamics, Humans, Hypertension, Pulmonary, Male, Middle Aged, Netherlands, Prospective Studies, Respiratory Function Tests, Risk Factors, Incidence, Logistic Models, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
